Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Insider Sells 4,991 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) insider Phillip Pang sold 4,991 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total value of $124,225.99. Following the completion of the transaction, the insider now directly owns 144,000 shares in the company, valued at $3,584,160. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NASDAQ:VIR opened at $24.54 on Thursday. The stock’s fifty day moving average is $23.22 and its 200 day moving average is $29.05. Vir Biotechnology, Inc. has a fifty-two week low of $18.21 and a fifty-two week high of $58.00. The firm has a market capitalization of $3.25 billion, a PE ratio of 2.71, a PEG ratio of 1.03 and a beta of -0.58.

Vir Biotechnology (NASDAQ:VIR – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $3.85 earnings per share for the quarter, beating the consensus estimate of $3.21 by $0.64. Vir Biotechnology had a return on equity of 96.39% and a net margin of 52.29%. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $811.05 million. During the same quarter in the prior year, the firm posted ($1.32) EPS. Vir Biotechnology’s quarterly revenue was up 59900.0% compared to the same quarter last year. As a group, analysts anticipate that Vir Biotechnology, Inc. will post 2.16 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Vir Biotechnology by 26.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,444 shares of the company’s stock worth $354,000 after purchasing an additional 1,780 shares during the period. CNA Financial Corp increased its stake in Vir Biotechnology by 14.7% in the fourth quarter. CNA Financial Corp now owns 13,752 shares of the company’s stock worth $576,000 after purchasing an additional 1,760 shares during the period. Alliancebernstein L.P. boosted its holdings in Vir Biotechnology by 22.6% in the fourth quarter. Alliancebernstein L.P. now owns 2,620,753 shares of the company’s stock worth $109,731,000 after acquiring an additional 483,261 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Vir Biotechnology by 4.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 726,536 shares of the company’s stock worth $30,421,000 after acquiring an additional 27,892 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Vir Biotechnology by 186.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,430 shares of the company’s stock worth $49,000 after acquiring an additional 930 shares in the last quarter. Institutional investors and hedge funds own 79.91% of the company’s stock.

Several brokerages have recently issued reports on VIR. TheStreet cut Vir Biotechnology from a “c-” rating to a “d+” rating in a report on Monday, March 28th. Needham & Company LLC decreased their price objective on Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, March 28th. Robert W. Baird raised Vir Biotechnology from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $36.00 to $28.00 in a report on Thursday, March 3rd. Finally, HC Wainwright decreased their price objective on Vir Biotechnology from $250.00 to $125.00 in a report on Thursday, May 12th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.33.

About Vir Biotechnology (Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

See Also